Physician profile
Christopher C Noggle
NPI 1154107209
$2,242.95
in general payments reported to CMS, 2019-2025
17 companies · $731 in 2025
The $731 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $439 · 2024: $1,073 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,242.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $668.52 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $492.16 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $179.55 | 2024-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $146.00 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Mycite |
| Alkermes, INC. | $141.21 | 2024 | Vivitrol, Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $134.74 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $106.95 | 2024-2025 | Uzedy, Austedo Xr |
| Corium, LLC | $82.03 | 2024 | Azstarys |
| Lundbeck LLC | $64.09 | 2024 | Rexulti |
| Tempus Ai, INC | $44.00 | 2024 | |
| Neurocrine Biosciences, INC. | $43.67 | 2024-2025 | Ingrezza |
| Indivior INC. | $37.97 | 2024 | Sublocade |
| Vanda Pharmaceuticals INC. | $23.53 | 2025 | Fanapt |
| Braeburn INC. | $22.26 | 2024 | Brixadi |
| Novo Nordisk INC | $21.68 | 2025 | Ozempic, Rybelsus |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.50 | 2024 | Trintellix |
| Axsome Therapeutics, INC. | $13.09 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Noggle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.